The activated pathways, cell metabolism, TMB, PD-L1 expression, and tumor immunogenicity led to different characteristics in the immune microenvironment, which further affected the sensitivity of HNSC patients to ICI therapy (Supplementary Figure S4). Here, CD274 is linked to neoplasm.